Meyrier A, Kourilsky O, Montay G, Le Verge R
Pathol Biol (Paris). 1979 Mar;27(3):181-8.
In 23 chronic renal patients serum and urinary concentrations of pipemidic acid were studied, the drug being given orally for 3 to 105 days. In 13 non-dialyzed patients, whose GFR varied from 4.5 to 36 ml/mn the dosage was 11.2 to 30 mg/kg/day. Maximum serum concentrations were comprised between 6 and 29 micrograms/ml. In 2 patients minor clinical side-effects indicated a maximum tolerance level of 25 micrograms/ml. Urinary concentrations remained elevated in spite of severe renal failure. In 10 hemodialyzed patients maximum predialysis levels varied from 5.6 to 28 micrograms/ml. No side-effects were noticed. The dialysance of pipemidic acid was high, due to a low molecular weight and to a binding to proteins which seems to be lower in uremics than in normal subjects. We conclude that pipemidic acid can be utilized in chronic renal patients, in taking advantage of low GFR's for obtaining serum bactericidal concentrations on susceptible organisms.
对23例慢性肾病患者进行了吡哌酸血清和尿液浓度的研究,患者口服该药3至105天。13例未进行透析的患者,其肾小球滤过率(GFR)在4.5至36 ml/分钟之间,剂量为11.2至30 mg/kg/天。血清最大浓度在6至29微克/毫升之间。2例患者出现轻微临床副作用,表明最大耐受水平为25微克/毫升。尽管存在严重肾衰竭,尿液浓度仍保持升高。10例进行血液透析的患者,透析前最大水平在5.6至28微克/毫升之间。未观察到副作用。由于分子量低且与蛋白质的结合在尿毒症患者中似乎低于正常受试者,吡哌酸的透析率很高。我们得出结论,吡哌酸可用于慢性肾病患者,利用低肾小球滤过率在易感生物体上获得血清杀菌浓度。